Based on the data from the Kote-Jarai et al. study, the strongest predictors for the presence of a germline BRCA2 mutation are a young age of onset of PCa and a family history of breast and/or ovarian cancer. The gene discussed is BRCA2; the disease is posterior cortical atrophy.